Evidence map›Paper›PMID 39939955›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma.

Huaikai Shi, Ta-Kun Yu, Ben Johnson, Sakthi Priya Selvamani, Ling Zhuang, Kenneth Lee, Sonja Klebe, Samuel Smith, Kirby Wong, Kate Chen and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Huaikai ShiAsbestos and Dust Disease Research Institute (ADDRI), 3 Hospital Road, Sydney, NSW, Concord, NSW, 2139, Australia. peter.shi@addri.org.au.
Ta-Kun YuAsbestos and Dust Disease Research Institute (ADDRI), 3 Hospital Road, Sydney, NSW, Concord, NSW, 2139, Australia.
Ben JohnsonAsbestos and Dust Disease Research Institute (ADDRI), 3 Hospital Road, Sydney, NSW, Concord, NSW, 2139, Australia.
Sakthi Priya SelvamaniAsbestos and Dust Disease Research Institute (ADDRI), 3 Hospital Road, Sydney, NSW, Concord, NSW, 2139, Australia.
Ling ZhuangAsbestos and Dust Disease Research Institute (ADDRI), 3 Hospital Road, Sydney, NSW, Concord, NSW, 2139, Australia.
Kenneth LeeSydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia.
Sonja KlebeAsbestos and Dust Disease Research Institute (ADDRI), 3 Hospital Road, Sydney, NSW, Concord, NSW, 2139, Australia.
Samuel SmithDepartment of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, 2050, Australia.
Kirby WongDepartment of Radiology, Royal Prince Alfred Hospital, Sydney, 2050, Australia.
Kate ChenDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, 2139, Australia.
Georgina ClarkSydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia.
Emma M RathVictor Chang Cardiac Research Institute, 405 Liverpool St, Darlinghurst, NSW, 2010, Australia.
Holly PearsonSingle Cell Genomics Facility, School of Biomedical Engineering, Faculty of Engineering and IT, The University of Technology Sydney, Ultimo, NSW, 2007, Australia.
David Gallego OrtegaSingle Cell Genomics Facility, School of Biomedical Engineering, Faculty of Engineering and IT, The University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Anthony LintonAsbestos and Dust Disease Research Institute (ADDRI), 3 Hospital Road, Sydney, NSW, Concord, NSW, 2139, Australia.
Steven KaoAsbestos and Dust Disease Research Institute (ADDRI), 3 Hospital Road, Sydney, NSW, Concord, NSW, 2139, Australia.
Pablo SilveiraDendritic Cell Research Group, ANZAC Research Institute, Sydney, NSW, 2139, Australia.
Yuen Yee ChengInstitute for Biomedical Materials & Devices (IBMD), Faculty of Science, The University of Technology Sydney, Ultimo, NSW, 15 Broadway, Ultimo, NSW, 2007, Australia. yuenyee.cheng@uts.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFinding effective and curative treatment for mesothelioma remains challenging. While the introduction of immunotherapy combinations using ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have offered hope for some patients, a large proportion of mesothelioma cases, particularly the epithelial subtype, have minimal benefit from this.

methodsOur study was inspired by the results of the AdvanTG-105 phase I clinical trial, which showed partial response with anti-TIGIT/PD-1 treatment in two epithelioid mesothelioma patients. Here, we conducted a comprehensive in vivo experiment involving eight animal treatment groups administered with either PBS (control group), cisplatin/pemetrexed, anti-PD-1, anti-PD-1 + anti-CTLA-4, anti-TIGIT, anti-PD-1 + anti-TIGIT, anti-PD-1 + anti-CTLA-4 + anti-TIGIT, and cisplatin/pemetrexed + anti-PD-1 + anti-TIGIT.

resultsOur results indicate that animals receiving anti-PD-1 + TIGIT exhibited a superior anti-tumour response, with 90% of the treatment group exhibiting an objective response, compared to 60%, 20% and 40% for the standard-of-care anti-PD-1 + CTLA-4, single-agent anti-PD-1 and cisplatin/pemetrexed treatment groups, respectively. Animals receiving anti-PD-1 + TIGIT displayed a significantly reduced average tumour size, with improved weight and survival rates, and fewer adverse effects than those receiving anti-PD-1 + CTLA-4 treatment. Anti-PD-1 + TIGIT-treated animals achieved complete tumour regression, with heightened effector CD8 + T cell and NK cell activity, remaining tumour-free for over 300 days without immune-related adverse events. After initial tumour elimination, anti-PD-1 + TIGIT-treated animals showed no tumour regrowth in the rechallenge experiment.

conclusionThese findings provide rationale for the development of an anti-PD-1 + TIGIT combination immunotherapy trial for mesothelioma patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsMesotheliomaProgrammed Cell Death 1 ReceptorReceptors, ImmunologicAnimalsCell Line, TumorFemaleHumansImmunotherapyMiceXenograft Model Antitumor AssaysImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTIGIT protein, human

Identifiers

PMID39939955
PMCPMC11816573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.